Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 6, 2009, Pages 558-563

  Johnson, John L ^a,g   Hadad, David Jamil ^b   Dietze, Reynaldo ^b   Maciel, Ethel Leonor Noia ^b   Sewali, Barrett ^c   Gitta, Phineas ^c   Okwera, Alphonse ^c,d   Mugerwa, Roy D ^c   Alcaneses, Mary Rose ^e   Quelapio, Maria Imelda ^e   Tupasi, Thelma E ^e   Horter, Libby ^a   Debanne, Sara M ^a   Eisenach, Kathleen D ^f   Boom, W Henry ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Ugandan National Tuberculosis and Leprosy Programme   (Uganda)

^e Tropical Disease Foundation   (Philippines)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antitubercular agents; Isoniazid; Rifampin; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK; SPUTUM CULTURE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; ISONIAZID; KAPLAN-MEIERS ESTIMATE; MALE; MYCOBACTERIUM TUBERCULOSIS; PROPORTIONAL HAZARDS MODELS; PYRAZINAMIDE; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 69949099207     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200904-0536OC     Document Type: Article

References (34)

1. Dutt A, Moers D, Stead WW. Smear- and culture-negative pulmonary tuberculosis: four-month short course chemotherapy. Am Rev Respir Dis 1989;139:867-870. (Pubitemid 19094306)
2. Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Am Rev Respir Dis 1981;124:138-142.
3. Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. Ann Acad Med Singapore 2002;31:175-181.
4. Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: results at 5 years. Am Rev Respir Dis 1989;139:871-876.
5. Balasubramanian R, Sivasubramanian S, Vijayan VK, Ramachandran R, Jawahar MS, Paramasivan CN, Selvakumar N, Somasundaram PR. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle 1990;71:253-258.
6. Hong Kong Chest Service/British Medical Research Council. A controlled clinical comparison of 6 and 8 months of antituberculous chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Am Rev Respir Dis 1991;143:262-267.
7. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis: first report: Results during chemotherapy. British Thoracic Association. Br J Dis Chest 1981;75:141-153. (Pubitemid 11096845)
8. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-1063.
9. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534.
10. Zierski M, Bek E, Long MW, Snider DE Jr. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis 1980;122:879-889. (Pubitemid 11207865)
11. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, Cronin W, Hooper N, Bishai W, Sterling TR. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004;38:731-736. (Pubitemid 38333871)
12. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-1693. (Pubitemid 33124328)
13. Tripathy SP. Relapse in tuberculosis. Indian J Tuberc 1981;28:45-57.
14. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117:744-751. (Pubitemid 30152215)
15. Andreu J, Caceres J, Pallisa E, Martinez-Rodriguez M. Radiological manifestations of pulmonary tuberculosis. Eur J Radiol 2004;51:139-149.
16. Gomes M, Saad R, Stirbulov R. Pulmonary tuberculosis: relationship between sputum bacilloscopy and radiological lesions. Rev Inst Med Trop Sao Paulo 2003;45:275-281. (Pubitemid 37408782)
17. Wilcke JT, Askgaard DS, Nybo Jensen B, Dossing M. Radiographic spectrum of adult pulmonary tuberculosis in a developed country. Respir Med 1998;92:493-497. (Pubitemid 28162160)
18. Matsuoka S, Uchiyama K, Shima H, Suzuki K, Shimura A, Sasaki Y, Yamagishi F. Relationship between CT findings of pulmonary tuberculosis and the number of acid-fast bacilli on sputum smears. Clin Imaging 2004;28:119-123. (Pubitemid 38402056)
19. Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, Maciel EL, do Valle Dettoni V, Horter L, Boom WH, et al. Cavitary disease and quantitative sputum bacillary load in pulmonary tuberculosis. J Clin Microbiol 2007;45:4064-4066.
20. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-415.
21. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406.
22. East African/British Medical Research Council. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Second East African/British Medical Research Council study. Am Rev Respir Dis 1976;114:471-475.
23. Hauck WW, Anderson S. A comparison of large-sample confidence interval methods for the difference of two binomial probabilities. Am Stat 1986;40:318-322.
24. Tu D. A comparative study of some statistical procedures in establishing therapeutic equivalence of nonsystemic drugs with binary endpoints. Drug Inf J 1997;31:1291-1300.
25. Falk A, O'Connor JB, Pratt PC, Webb WR, Wier JA, Wolinsky E. Chapter 6. Classification of pulmonary tuberculosis. Diagnostic standards and classification of tuberculosis, 12th ed. New York: National Tuberculosis and Respiratory Disease Association; 1969.
26. Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B. Time to detection of mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998;113:379-386. (Pubitemid 28110014)
27. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64:2062-2069.
28. Boshoff HIM, Barry CE. Tuberculosis: metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005;3:70-80.
29. Dick T. Dormant tubercle bacilli: the key to more effective TB chemotherapy? J Antimicrob Chemother 2001;47:117-118.
30. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66:219-225. (Pubitemid 16150082)
31. Mitchison DA. Understanding the chemotherapy of tuberculosis: current problems. J Antimicrob Chemother 1992;29:477-493.
32. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3:323-324. (Pubitemid 46789271)
33. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466. (Pubitemid 44875946)
34. Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009;9:162-172.